Equities

KPC Pharmaceuticals Inc

600422:SHH

KPC Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)20.17
  • Today's Change-0.38 / -1.85%
  • Shares traded9.26m
  • 1 Year change-18.73%
  • Beta0.8917
Data delayed at least 15 minutes, as of May 31 2024 08:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

KPC Pharmaceuticals, Inc. is a China-based company principally engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company's main products include natural herbal medicines, traditional Chinese medicines and chemical synthetic drugs, such as central nervous system drugs, cardiovascular and cerebrovascular drugs, anti-parasitic drugs, anti-microbial drugs, anti-gout drugs, hormones and endocrine drugs, hemorrhoids medicines and anti-inflammatory drugs, among others. The Company is also engaged in the production of health products and provision of medical services.

  • Revenue in CNY (TTM)7.65bn
  • Net income in CNY432.35m
  • Incorporated1995
  • Employees5.05k
  • Location
    KPC Pharmaceuticals IncNo. 166Keyi Road, High-tech Development ZoneKUNMING 650106ChinaCHN
  • Phone+86 87 168324311
  • Fax+86 87 168324267
  • Websitehttp://www.kpc.com.cn
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sunshine Guojian Pharmcutcl Shngh Co Ltd1.07bn352.22m13.89bn965.0039.442.78--12.940.5710.5711.748.090.20781.149.251,112,527.006.611.326.931.4177.8580.7431.816.556.66--0.018.2522.84-2.35497.63-4.4421.22--
Changchun BCHT Biotechnology Co1.92bn543.19m14.06bn1.24k25.843.44--7.341.321.324.649.880.41160.84591.551,543,550.0011.679.9514.1412.8189.9086.6328.3624.032.03--0.015810.5570.3012.36175.9831.3721.04--
Suzhou Zelgen Biopharmaceuticals Co Ltd386.57m-260.85m14.73bn867.00--9.24--38.10-1.00-1.001.496.020.16210.25943.75445,874.00-11.74-27.13-20.82-39.2092.2992.75-72.40-220.712.15--0.3842--27.83211.8139.08--41.38--
Anhui Huaheng Biotechnology Co Ltd2.04bn454.44m14.93bn1.69k32.927.80--7.322.882.8812.9212.150.61965.598.041,205,674.0013.7116.7421.5922.4138.4939.2122.1322.340.4552155.980.455225.2036.6335.7240.3242.8482.09--
BrightGene Bio-Medical Technology Co Ltd1.21bn195.77m15.01bn1.16k77.766.18--12.360.45690.45692.875.750.24631.694.431,051,700.003.436.534.297.9354.9256.9313.9319.901.454.860.478729.3115.9423.68-15.5122.5629.13--
Liaoning Cheng Da Co Ltd11.18bn17.48m15.11bn3.36k760.000.5182--1.350.0130.0137.3419.070.23584.416.493,330,121.00-0.53663.59-0.76445.2116.0314.15-2.289.890.7792--0.283415.93-25.97-10.97-80.95-21.267.04--
KPC Pharmaceuticals Inc7.65bn432.35m15.27bn5.05k35.042.82--2.000.57570.575710.207.150.80212.482.621,513,702.004.635.427.769.1343.1243.685.775.701.4653.930.168835.75-6.991.6416.055.79-21.3314.87
Shanghai Shyndec Pharmaceutical Co Ltd11.78bn843.91m15.33bn11.61k17.881.21--1.300.63940.63948.959.480.60693.086.611,014,487.005.754.858.508.1737.0943.009.487.031.82--0.105717.52-6.861.2910.21-0.3897-2.210.00
Dizal Jiangsu Pharmaceutical Co Ltd172.61m-1.09bn16.40bn581.00--23.54--95.00-2.67-2.670.4221.680.10080.32156.78297,086.40-63.79-46.02-82.62-52.9996.4157.53-632.90-2,081.541.74--0.4557----18.29-50.50--21.35--
Jiang Zhong Pharmaceutical Co Ltd4.30bn734.24m16.41bn4.01k22.363.98--3.811.171.176.836.550.66984.3413.621,071,799.0012.3510.8218.8215.0864.0165.0218.4418.171.47--0.006182.8813.0020.1218.408.5411.4740.99
Data as of May 31 2024. Currency figures normalised to KPC Pharmaceuticals Inc's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

13.47%Per cent of shares held by top holders
HolderShares% Held
Fullgoal Fund Management Co., Ltd.as of 30 Sep 202326.57m3.51%
Zhong Ou Asset Management Co., Ltdas of 31 Dec 202319.37m2.56%
China Investment Corp. (Investment Management)as of 30 Sep 202311.81m1.56%
GF Fund Management Co., Ltd.as of 31 Dec 202311.06m1.46%
ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 20238.01m1.06%
China Universal Asset Management Co., Ltd.as of 31 Dec 20235.61m0.74%
HuaAn Fund Management Co., Ltd.as of 31 Dec 20235.18m0.68%
China Southern Asset Management Co., Ltd.as of 30 Jun 20235.17m0.68%
First Seafront Fund Management Co., Ltd.as of 31 Dec 20234.86m0.64%
Cinda Fund Management Co. Ltd.as of 31 Dec 20234.31m0.57%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.